ASCO

Gilead, Pfizer & Tragic Paradox: Drug Updates & News

by

Archyde The Looming Paradox in Cancer Treatment: ASCO 2024 Signals a Shift Towards Personalized, Yet Increasingly Unequal, Access Despite decades of progress, a troubling paradox is emerging in cancer care. While the American Society of Clinical Oncology (ASCO) 2024 meeting showcased remarkable advancements in targeted therapies and immunotherapies – particularly in breast cancer – these … Read more

First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

by

Fruquintinib Regimen in ESCC | Image Credit: ©Ashling Wahner & MJH Life Sciences Using AI Frontline treatment with fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin elicited responses with an acceptable safety profile in patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a phase 2 study (NCT06010212) presented during the 2025 … Read more